4/17
10:56 am
imnn
Imunon (IMNN) was given a new $10.00 price target by Maxim Group.
Low
Report
Imunon (IMNN) was given a new $10.00 price target by Maxim Group.
4/17
09:40 am
imnn
Imunon (IMNN) is now covered by Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.
Low
Report
Imunon (IMNN) is now covered by Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.
3/31
05:08 pm
imnn
Imunon Inc (IMNN) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Management [Yahoo! Finance]
Low
Report
Imunon Inc (IMNN) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Management [Yahoo! Finance]
3/31
03:47 pm
imnn
Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/31
03:47 pm
imnn
Imunon targets ~80 OVATION 3 patients in the next 12 months as cash runway extends into H2 2026 [Seeking Alpha]
Low
Report
Imunon targets ~80 OVATION 3 patients in the next 12 months as cash runway extends into H2 2026 [Seeking Alpha]
3/31
08:13 am
imnn
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study [Yahoo! Finance]
Low
Report
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study [Yahoo! Finance]
3/31
08:00 am
imnn
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
Medium
Report
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
3/26
05:03 am
imnn
IMNN: Updated OVATION 2 Data Shows 14.7-Month Improvement in OS Compared to SoC [Yahoo! Finance]
Medium
Report
IMNN: Updated OVATION 2 Data Shows 14.7-Month Improvement in OS Compared to SoC [Yahoo! Finance]
3/25
08:05 am
imnn
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
Medium
Report
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
3/24
08:00 am
imnn
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
Low
Report
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
2/5
08:05 am
imnn
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
Medium
Report
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
1/24
05:08 am
imnn
Imunon (NASDAQ:IMNN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Imunon (NASDAQ:IMNN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.